BRITTANY PROPOGGIO: Open Payments
NPI 1407632870 · BOULDER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,380 in 111 payments from 15 companies in 2025. Trend: 2023 $51 · 2024 $2,670 · 2025 $2,380
Food & beverage: $2,380
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $673 |
| Gilead Sciences, Inc. | 13 | $266 |
| Janssen Biotech, Inc. | 7 | $239 |
| Regeneron Healthcare Solutions, Inc. | 10 | $225 |
| GENZYME CORPORATION | 5 | $137 |
| Aimmune Therapeutics, Inc. | 7 | $134 |
| Lilly USA, LLC | 6 | $129 |
| Celltrion USA Inc. | 4 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| Madrigal Pharmaceuticals | 3 | $86 |
Products named: DUPIXENT, RINVOQ, LINZESS, TREMFYA, ZENPEP, OMVOH, VEGZELMA, ENTYVIO.
Industry payments across CO — which companies pay providers there.
